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ARTICLE
Targeting PFKFB3 radiosensitizes cancer cells and
suppresses homologous recombination
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The glycolytic PFKFB3 enzyme is widely overexpressed in cancer cells and an emerging anti-
cancer target. Here, we identify PFKFB3 as a critical factor in homologous recombination
(HR) repair of DNA double-strand breaks. PFKFB3 rapidly relocates into ionizing radiation
(IR)-induced nuclear foci in an MRN-ATM-γH2AX-MDC1-dependent manner and co-
localizes with DNA damage and HR repair proteins. PFKFB3 relocalization is critical for
recruitment of HR proteins, HR activity, and cell survival upon IR. We develop KAN0438757,
a small molecule inhibitor that potently targets PFKFB3. Pharmacological PFKFB3 inhibition
impairs recruitment of ribonucleotide reductase M2 and deoxynucleotide incorporation upon
DNA repair, and reduces dNTP levels. Importantly, KAN0438757 induces radiosensitization
in transformed cells while leaving non-transformed cells unaffected. In summary, we identify
a key role for PFKFB3 enzymatic activity in HR repair and present KAN0438757, a selective
PFKFB3 inhibitor that could potentially be used as a strategy for the treatment of cancer.
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T
he cellular response to DNA double-strand breaks (DSBs)
is orchestrated by the DNA damage response (DDR) where
the ataxia-telangiectasia mutated (ATM) kinase plays a
central role1. ATM rapidly becomes activated by the MRE11/
RAD50/NBS1 sensor complex upon ionizing radiation (IR)-
induced DSBs2. Once activated, ATM phosphorylates the tail of
H2AX at Ser139 (γH2AX) on the chromatin ﬂanking the DSB,
which attracts binding of the mediator of DNA damage check-
point protein 1 (MDC1), altogether forming a complex and
feedback loop resulting in ampliﬁcation and stabilization of
γH2AX. This serves as a platform for recruitment and accumu-
lation of additional DNA repair factors3,4. DSB repair occurs
primarily via the error-prone non-homologous end-joining
(NHEJ) or with the homologous recombination (HR) pathway
in the S and G2 phases of the cell cycle, when a sister chromatid is
available as a template. The HR process requires DNA end-
resection where single-stranded DNA (ssDNA) ﬁrst is generated
via degradation of one of the strands at both sides of the break, a
process promoted by BRCA1. The ssDNA overhangs rapidly
become coated with the ssDNA binding protein Replication
protein A (RPA). Upon initiation of HR, RPA is replaced by the
RAD51 recombinase which locates homology in sister chromatids
and catalyzes strand invasion and strand pairing5,6.
The homodimeric 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatases (PFKFBs) are key regulatory enzymes in the
glycolysis7. These bifunctional enzymes synthesize and degrade
fructose-2,6-bisphosphate (F-2,6-P2), which acts as an allosteric
activator for the rate-limiting enzyme and committed step in
glycolysis, i.e., 6-phophofructo-1-kinase (PFK-1)8. In contrast to
the PFKFB isoforms 1, 2, and 4, which are constitutively
expressed in testes/kidney/heart and liver/muscle, PFKFB3 is an
inducible isoform9 with increased expression in response to
hypoxia, extracellular acidosis, and inﬂammation. PFKFB3 also
stands out with a kinase to bisphosphatase ratio of 740:1, while
the other isoforms display a more balanced ratio closer to unity10.
Consistent with being a transcriptional target of several oncogenic
transcription factors (HIF-1α, Akt, PTEN), PKFBF3 protein
expression is increased in several cancers seemingly independent
of tissue of origin compared to normal matched tissues, making
this a recognized target for anti-cancer treatment11–15. In addi-
tion, a kinase-activating phosphorylation of PFKFB3, resulting in
a further elevation of the kinase to bisphosphatase ratio, is more
frequently encountered in cancers16. High PFKFB3 mRNA
expression correlates with poor survival in renal cancer, pro-
gression-free, and distant metastatic-free survival in human epi-
dermal growth factor receptor 2 (HER2) positive breast cancer
patients17,18. Depletion of PFKFB3 by RNA interference in cancer
cells delays cell cycle progression and inhibits anchorage-
independent cell growth as well as reduces Ras-induced tumor
growth in mice19,20. Interestingly, a recent study showed potential
involvement of cytosolic glycolysis via PFKFB3 in the p53-
mediated response to UV damage21. However, nuclear PFKFB3
drives cancer cell proliferation without affecting intracellular
glycolysis to a measurable extent22, suggesting non-canonical
functions of PFKFB3 in cancer.
Here, we reveal a role for PFKFB3 in HR repair of DNA DSBs
in cancer cells. We demonstrate that PFKFB3 rapidly relocates
into IR-induced nuclear foci in an ATM-γH2AX-MDC1-
dependent manner and promotes recruitment of HR factors,
HR activity, and recovery from IR-induced cell cycle arrest.
Through drug discovery efforts, we develop and validate a
PFKFB3 inhibitor, KAN0438757, which selectively inhibits
proliferation of transformed cells while sparing non-
transformed cells. Inhibition of PFKFB3 enzymatic activity by
KAN0438757 impairs IR-induced recruitment of ribonucleotide
reductase (RNR) M2 and deoxynucleotide incorporation upon
DNA repair. Consistent with this, impairment in replication
fork progression by KAN0438757 was restored by nucleoside
supplementation. In conclusion, we identify a regulatory role
for PFKFB3 enzymatic activity in HR repair and our data
suggests that PFKFB3 inhibition by KAN0438757 could be an
attractive approach to increase sensitivity to therapeutically
induced DNA breaks.
Results
PFKFB3 is recruited into foci upon ionizing radiation. In an
analysis of publically available microarray data sets, we identiﬁed
the PFKFB3 mRNA to be upregulated in radiotherapy resistant
patients both before and after radiotherapy compared to radio-
sensitive patients (Supplementary Figure 1). These resistant
patients are marked by increased ability to repair IR-induced
DNA breaks23. This together with identifying PFKFB3 in
genome-wide siRNA screens aiming to detect DDR factors24,25,
prompted our interest in investigating a previously unknown role
for PFKFB3 in HR repair. To investigate a potential role for
PFKFB3 in DSB repair, we determined the localization of PFKFB3
using in situ cell fractionation26 following induction of DSBs by
IR in U2OS and BJ RAS (hTERT immortalized ﬁbroblasts
transformed with SV40 and RAS) cells. We observed a rapid
increase in focal accumulation of PFKFB3 in the nuclei that
reached maximum levels at 0.5 h post IR coinciding with the
induction of phosphorylated H2AX (γH2AX) (Fig. 1a–c, Sup-
plementary Figure 3a, b). The IR-induced increase in PFKFB3
was dynamic and decreased at 2 h, while the γH2AX levels
remained high, thus PFKFB3 is recruited early in the DDR
(Fig. 1a, b). The increase of PFKFB3 and γH2AX upon IR also
coincided with them co-localizing in foci, notably the co-
localization remained high at 2 h post-IR (Fig. 1d).
To gain insight into the mechanism behind this, rapid
accumulation of PFKFB3, U2OS, and BJ RAS cells were treated
with inhibitors against the most upstream DDR kinases ATM,
ATM- and Rad3-related (ATR) as well as the DNA-dependent
protein kinase (DNA-PK) prior to IR (Supplementary Figure 2a).
The IR-induced focal accumulation of PFKFB3 and γH2AX, as
well as co-localization between the proteins, was blocked upon
ATM inhibition, the major transducer in the IR-induced DDR
(Fig. 1a–c, Supplementary Figure 3a, b). Neither inhibition of
ATR nor DNA-PK affected the rapid recruitment of PFKFB3 or
its co-localization with γH2AX upon IR and resulted in retention
of PFKFB3 at 2 h post-IR (Fig. 1a–c, Supplementary Figure 3a, b).
Consistent with ATM being the major transducer in the IR-
induced DDR response27, ATR and DNA-PK inhibition did not
impair the γH2AX recruitment upon IR as compared to DMSO
treatment (Fig. 1a, c, Supplementary Figure 3a, b). However, both
ATR and DNA-PK are important for functional DDR27,
suggesting that PFKFB3 is retained in nuclear foci upon impaired
DDR signaling downstream of ATM and γH2AX. Consistent
with activation of ATM upon DNA damage being under the
dependence of the MRN complex28, inhibition of the MRN
complex by Mirin29 blocked the IR-induced recruitment of
PFKFB3 (Supplementary Figure 3c).
To elucidate the signaling pathways downstream of ATM that
modulate PFKFB3 recruitment we next inhibited γH2AX and
MDC1 by siRNA (Supplementary Figure 2b, c). RNAi-mediated
silencing of H2AX and MDC1 effectively reduced the recruitment
of PFKFB3 into IR-induced foci (Fig. 2a). The PFKFB3 foci were
also abolished with two different siRNAs targeting PFKFB3
indicating speciﬁc staining (Fig. 2a, Supplementary Figure 2d).
Thus, we conclude that upon IR, the MRN complex, ATM,
γH2AX, and MDC1 stimulate re-localization of PFKFB3 into
nuclear foci.
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PFKFB3 regulates homologous recombination repair. To
examine the role of PFKFB3 in DNA repair in greater detail, we
assessed co-localization between PFKFB3 foci and foci of ATM-
dependent DNA damage and repair factors upon induction of
DSBs by IR in U2OS and BJ RAS cells. PFKFB3 foci co-localized
with IR-induced foci of γH2AX, 53BP1, RPA, and BRCA1
(Fig. 2b, Supplementary Figure 4). To investigate whether the
recruitment of these factors is dependent on PFKFB3, we induced
DSBs by IR in PFKFB3 siRNA transfected cells. PFKFB3
knockdown abolished recruitment of the HR repair factors
RPA32 and BRCA1 into foci upon IR, while focal accumulation
of the upstream DNA damage markers 53BP1 and γH2AX was
unaffected (Fig. 2c, d). Notably, also recruitment of RAD51 was
blocked upon PFKFB3 knockdown (Fig. 2c, d). As RPA32,
BRCA1, and RAD51 are essential for functional HR repair, we
next evaluated the importance of PFKFB3 in HR efﬁciency
employing the DR-GFP assay in U2OS cells30. Importantly, HR
repair activity was decreased down to 40% upon knockdown of
PFKFB3 with two different siRNAs (Fig. 2e). To conﬁrm that the
block in HR repair activity upon PKFBF3 silencing was not a
secondary effect due to a potential reduction of cells in the S-G2/
M phases, we performed cell cycle analysis at the time for the DR-
GFP assay (72 h siRNA treatment). The PFKFB3 knockdown
population displayed a minor decrease of cells of approximately
7% in the S phase, however, this modest drop is unlikely to
account for a 60% decrease in HR activity (Fig. 2f).
IR delays cell cycle progression via ATM, which also signals for
DNA repair prior to entry into mitosis3. Impaired HR will result
in delayed or non-functional DNA repair. Thus, we next
investigated potential effects on the cell cycle distribution upon
PFKFB3 depletion in combination with IR. While untreated
control cells displayed a normal G2/M population upon silencing
of PFKFB3, the IR-treated cells showed a delayed G2/M phase
progression compared to control (Fig. 2f). To determine the long-
term effects on cancer cell survival upon PFKFB3 depletion in
combination with IR, clonogenic survival assays were performed.
Consistent with PFKFB3 supporting cancer cell proliferation,
PFKFB3 silencing on its own reduced clonogenic survival
(Fig. 2g). Importantly, PFKFB3 silencing signiﬁcantly enhanced
radiosensitivity with approximately 6-fold as compared siControl
treatment with IR (Survival Fraction 0.05 versus 0.28) (Fig. 2g).
Thus, we conclude that upon IR, PFKFB3 is required for
recruitment of RPA and RAD51, functional HR repair of DSBs,
cell cycle progression, and long-term cell survival.
Development of PFKFB3 inhibitor. To further evaluate the role
of PFKFB3 enzymatic activity in supporting HR, we treated U2OS
cells with the previously described PFKFB3 inhibitor 3-(3-pyr-
idinyl)-1-(4-pyridinyl)-2-propen-1-one (3-PO)31 in combination
with IR. However, IR-induced recruitment of RPA32 and RAD51
to DNA breaks was unaffected in the presence of 3-PO (Sup-
plementary Figure 5a, b), inconsistent with the PFKFB3 siRNA
data (Fig. 2c). We also used the DR-GFP reporter systems to
evaluate the HR repair activity. However, treatment of U2OS cells
with 3-PO did not decrease HR activity (Supplementary Fig-
ure 5c), again inconsistent with the results from PFKFB3 siRNA
experiments (Fig. 2e). To further understand the utility of 3-PO
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Fig. 1 ATM signaling stimulates PFKFB3 recruitment upon DNA damage induction. a Confocal analysis of DNA damage, γH2AX, and nuclear localization of
PFKFB3 in U2OS cells following treatment with inhibitors (6 h) as indicated, subjected to IR (6 Gy), or left untreated, n= 3 independent experiments. Scale
bar, 10 μm. b Scatter dot plot representing the PFKFB3 nuclear intensity in (a) as quantiﬁed using CellProﬁler, n > 100 cells/treatment. ***P < 0.001; one-
way ANOVA analysis. c Scatter dot plot representing the γH2AX nuclear intensity in (a) as quantiﬁed using CellProﬁler, n > 100 cells/treatment. **P < 0.01,
***P < 0.001; one-way ANOVA analysis. d Bars representing the percentage of PFKFB3 and γH2AX foci that co-localize in (a) as quantiﬁed using
CellProﬁler, n > 100 cells/treatment. Data are displayed as means ± SEM, ***P < 0.001, one-way ANOVA was used to calculate statistical signiﬁcance
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06287-x ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3872 | DOI: 10.1038/s41467-018-06287-x | www.nature.com/naturecommunications 3
as a PFKFB3 inhibitor, its effect on human recombinant PFKFB3
enzyme as well as production of fructose-2,6-bisphosphatase in
cells were studied. In line with previous publications32,33, we
could not achieve an IC50 value for the 3-PO compound in the
PFKFB3 activity assays (Supplementary Figure 5d). The apparent
lack of PFKFB3 inhibition in our hands, in combination with the
lack of an available crystal structure conﬁrming binding of 3-PO
to PFKFB3, prompted us to search for alternative inhibitors.
In the search for inhibitors of the enzymatic activity of
PFKFB3, we screened 50,000 diverse compounds (Fig. 3a,
Supplementary Fig. 6a). Representative compounds from hit
series and singletons were tested for binding to PFKFB3 using
a siH2AX
No IR
P
F
K
F
B
3
M
e
rg
e
d
siPFKFB3 #1siControl siPFKFB3 #2
IR (2 h)
e
gf
d
siMDC1siControl
N
o 
IR
si
C
on
tro
l
si
PF
KB
F3
 #
1
si
PF
KF
B3
 #
2
si
H
2A
.X
si
M
D
C
1
0
5
10
15
20
25
P
F
K
F
B
3
 f
o
c
i 
p
e
r 
n
u
c
le
i ***
***
0
0.1
0.2
0.3
0.4
0.5
0.8
1.0
1.2
S
u
rv
iv
a
l 
fr
a
c
ti
o
n
fo
ld
 s
iC
tr
l
0.05
0.40
0.28
***
***
b
N
o
 I
R
IR
RPA32
s
iC
o
n
tr
o
l
s
iC
o
n
tr
o
l
s
iP
F
K
F
B
3
Merge53BP1 RAD51 BRCA1Merge MergeMerge MergeγH2AX
R
P
A
 i
n
te
n
s
it
y
 (
A
.U
)
R
R
A
 p
o
s
it
iv
e
 c
e
lls
 
R
A
D
5
1
 p
o
s
it
iv
e
 c
e
lls
 
R
A
D
5
1
 i
n
te
n
s
it
y
 (
A
.U
)
48% 12% 25% 8%
0 0
200
200
400
400
300
100
600
***
***
20
40
60
80
100
120
F
o
c
i 
p
e
r 
n
u
c
le
i
27
69
108
55
siCtrl
siPFKFB3
RAD51 RPA
G0/G1
0
20
40
60
C
e
lls
 (
%
)
+–
–
siPFKFB3
siControl +
– +
–+
– +
–+
– +
–+
– +
–+
– +
–+
– +
–+
– +
–+
– +
–+
– +
–+
– +
–+
– +
–+
G0/G1 G0/G1 G0/G1S S S SG2/M G2/M G2/M G2/M
24 h (0 h prior to IR) 24 h post IR 48 h 72 h
IR (2 h)
P
F
K
F
B
3
M
e
rg
e
d
γH2AX BRCA1 RPA32 53BP1
– + – + – + – +
0
20
40
60
80
100
F
o
c
i 
c
o
-l
o
c
a
liz
in
g
 w
it
h
 P
F
K
F
B
3
 (
%
)
IR
γH2AX BRCA1 RPA2 53BP1
85
27
42
48
10
0
6 5
***
***
***
*
c
No ISceI siControl
siControl
siPFKFB3 oligo 1
siPFKFB3 oligo 2
siRAD51
0
20
40
60
80
100
H
R
 a
c
ti
v
it
y
 (
%
)
****
***
si
C
trl
si
PF
KF
B3
si
C
trl
si
PF
KF
B3
siControl, no IR
siPFKFB3, no IR
siControl, 2Gy
siPFKFB3, 2Gy
***
***
***
***
**
**
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06287-x
4 NATURE COMMUNICATIONS |  (2018) 9:3872 | DOI: 10.1038/s41467-018-06287-x | www.nature.com/naturecommunications
Saturation Transfer Difference NMR to conﬁrm reversible
binding. Competition experiments with ATP were used to
identify ATP-competitive and non-ATP-competitive binders
(Supplementary Figure 6b). This effort lead to the identiﬁcation
and further development of a series of phenylsulfonamido
salicylic acids that rendered sub-µM inhibitors of PFKFB3. These
non-ATP-competitive ligands were selected for further optimiza-
tion to avoid cross activity with other kinases (Fig. 3a,
Supplementary Figure 6b). A representative of this compound
series is illustrated by KAN0438241 in Fig. 3b, which demon-
strated selectivity for the kinase activity of PFKFB3 versus the
other isoforms PFKFB1, PFKFB2, and PFKFB4 (Supplementary
Figure 6c). Signiﬁcant cross-reactivity is only observed for
PFKFB4, although the selectivity window is about 20-fold with
IC50 values of 0.19 and 3.6 µM, respectively (Supplementary
Figure 6c). The sub-µM potency for PFKFB3 was also conﬁrmed
using isothermal titration calorimetry as illustrated in Figure S6D
and co-crystal structures demonstrated binding in the active site,
mimicking several of the interactions made by the endogenous
substrate fructose-6-phosphate (F6P) (Fig. 3e).
Further characterization of KAN0438241 and its ester
KAN0438757 (Fig. 3b), which was designed to increase cell
permeability and efﬁcient intracellular hydrolysis to release the
active compound, involved examination of their impact on the
proximal biomarker F-2,6-P2 in several different cell lines
34.
Whereas the salicylate was only weakly active with low µM
potency in the cellular setting (Fig. 3c), the ester demonstrated
signiﬁcant suppression of intracellular F-2,6-P2 levels with sub-
µM IC50 values in cell lines representing pancreatic, gastric, and
colon cancer (Fig. 3c, Supplementary Figure 6e). In the same cell
lines, KAN0438757 was also demonstrated to signiﬁcantly reduce
cell viability following prolonged incubation times (Figure S6F).
Consistent with PFKFB3 being overexpressed in cancer, the
viability of peripheral blood mononuclear cells (PBMCs) was not
affected upon inhibition of PFKFB3 by KAN0438757 (Supple-
mentary Figure 6f).
The effect on intracellular F-2,6-P2 levels is in contrast to what
we observed in the in vitro enzymatic assay for PFKFB3, where
the ester is largely inactive (Fig. 3d). Given the binding pose,
which involves important interactions for the carboxylate (Fig. 3e,
f), the lack of activity for the ester in a non-cellular setting is not
surprising. Using the cellular thermal shift assay (CETSA)35,36,
we could also conﬁrm that KAN0438757 demonstrated intracel-
lular target engagement for PFKFB3 in the same concentration
range as that observed using the Van Schaftingen assay (Fig. 3g).
The target engagement by KAN0438757 persisted at 24 and 72 h
of treatment (Supplementary Figure 7a–d), with the later
time-point corresponding to the viability measurement, indicat-
ing PFKFB3 inhibition and compound stability during the entire
time-course of the viability assay. To further validate
KAN0438241 as a useful chemical tool for probing cellular
PFKFB3 activity, we examined the kinome-wide selectivity proﬁle
of KAN0438757 and its active metabolite KAN0438241 with
DiscoveRx’s KINOMEscan technology37. Both compounds dis-
played high selectivity (SScore(35)= 0) at 2 µM. The results
demonstrated that no signiﬁcant binding could be detected in any
of the 97 targets in the diverse scanEDGEsm set of kinases
(Supplementary Figure 6g and Supplementary Data 1).
DNA repair is dependent on PFKFB3 kinase activity. To
investigate if the impaired HR upon PFKFB3 silencing is
dependent on the kinase activity of PFKFB3, we examined the IR-
induced recruitment of RPA32 and RAD51 into repair foci in
KAN0438757-treated U2OS cells. The recruitment of both HR
factors was disrupted upon inhibition of PFKFB3 (Fig. 4a, b),
consistent with the results observed upon inhibition of PFKFB3
expression using siRNA knockdown (Fig. 2d). Consistent with
PFKFB3 being downstream of the MRN complex, treatment with
KAN0438757 prior to IR did not affect the IR-induced Mre11 or
Nbs1 foci formation in comparison to treatment with Mirin that
completely blocked induction of both the components of the
MRN complex (Supplementary Figure 8a, b). Due to the
decreased recruitment of RPA and RAD51, the DR-GFP reporter
system was next used to investigate the impact of KAN0438757
on HR repair activity. Treatment of U2OS cells with
KAN0438757 decreased HR activity down to 10% as compared to
vehicle-treated cells and notably even more so than inhibition of
ATR, a key component in HR (Fig. 4c). To conﬁrm that the block
in HR repair activity upon PKFBF3 inhibition was not a sec-
ondary effect due to a potential reduction of cells in the S-G2/M
phases, we performed cell cycle analysis at the time for the DR-
GFP assay. Similar to PFKFB3 knockdown, the KAN0438757
population displayed a modest decrease of cells in the S phase
(Supplementary Figure 8c). Notably, treatment with the 3-PO
compound resulted in a similar cell cycle proﬁle as KAN0438757
and siPFKFB3 (Supplementary Figure 8c), but without affec-
ting HR activity (Supplementary Figure 5c). Thus, the small effect
on the cell cycle distribution upon PFKFB3 knockdown or inhi-
bition is not sufﬁcient to alter the HR activity in the DR-GFP
assay.
We hypothesized that disrupted HR activity upon PFKFB3
inhibition in combination with IR would result in unrepaired
DSBs and thereby sustained high levels of DSBs. Thus we
quantiﬁed the focal accumulation of γH2AX, a sensitive marker
Fig. 2 PFKFB3 promotes homologous recombination repair. a Confocal analysis of nuclear localization of PFKFB3 in U2OS cells following treatment with
siRNAs (24 h) as indicated, subjected to IR (6 Gy, 2 h recovery), or left untreated, n= 3 independent experiments. Scale bar, 10 μm. To the right, bar chart
showing PFKFB3 foci as quantiﬁed using CellProﬁler, n > 100 cells/treatment. Data are displayed as means ± SEM. ***P < 0.001; one-way ANOVA analysis.
b Confocal images of co-localization between PFKFB3 and indicated proteins in U2OS cells upon IR (6 Gy, 2 h recovery). White arrows indicate co-localized
foci, n= 2 independent experiments. Scale bar, 10 μm. To the right, bar graph representing the percentage of PFKFB3 foci that co-localized with indicated
proteins as quantiﬁed using CellProﬁler. n > 100 cells/condition. Data displayed as means ± SEM. ***P < 0.001, *P < 0.05; Student’s t-test. c U2OS cells
were treated with indicated siRNAs for 24 h, subjected to IR at 6 Gy (2 h recovery) and immunostained for indicated proteins, n= 3 independent
experiments. Scale bar, 10 μm. d Scatter dot plot representing the RAD51 or RPA32 nuclear intensity in (c) as quantiﬁed using CellProﬁler. To the right, bars
showing RAD51 or RPA foci per nuclei in (c). n > 500 cells/treatment. Data displayed as means ± SEM. ***P < 0.001; Student’s t-test. e HR activity after
treatment of U2OS DR-GFP cells with indicated siRNAs as assessed by FACS analysis, whereby the siControl cells are set as reference cells (100%
activity). Data are displayed as means ± SEM, n= 3. **P < 0.01, ***P < 0.001; one-way ANOVA analysis. f DNA histograms of U2OS cells treated with
indicated siRNAs for 24 h then subjected to IR at 2 Gy (24 h recovery) or left untreated for 48 and 72 h. Cells were ﬁxed and DNA content was assessed
using propidium iodide staining and ﬂow cytometry. Data are displayed as means ± SEM, n= 3. **P < 0.01, ***P < 0.001; one-way ANOVA analysis.
g Colony formation of U2OS cells 10 days after treatment with 10 nM siControl or 10 nM siPFKFB3 in combination with 2 Gy or left untreated, was assessed
by staining with 4% methylene blue in methanol and counting colonies. Data are displayed as means fold over siControl no IR ± SEM, n > 5. ***P < 0.001;
one-way ANOVA analysis
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Following measurements of inhibition of human recombinant enzyme, the inhibitory effects on PFKFB3 in cells were demonstrated by intracellular
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g Target engagement and thermal stabilization of PFKFB3 by 10 µM KAN757 (KAN0438757) as compared to DMSO in U2OS cells, assessed by CETSA. Band
intensities were quantiﬁed using ImageJ, PFKBF3 levels were normalized against β-actin. To the right, bar graph representing the percentage of non-denatured
PFKFB3 relative to DMSO at 42 °C, shown is a representative experiment of n= 2
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of DSBs38, at 2 and 24 h post-IR in KAN0438757-treated cells.
PFKFB3 inhibited cells had signiﬁcantly higher levels of γH2AX
foci, as well as the percentage of γH2AX positive cells, compared
to vehicle at 24 h post-IR (Fig. 4d), indicative of reduced repair of
the IR-induced DNA damage. Consistent with the impaired HR
activity and sustained high levels of γH2AX at 24 h post-IR in
PFKFB3 inhibitor-treated cells, we observed an increased
accumulation of cells in the G2/M phase upon IR in combination
with KAN0438757 treatment at 24 h post-IR, a phenotype not
seen with 3-PO (Supplementary Figure 8c).
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We next assessed how KAN0438757 affects DDR signaling
following IR and in comparison to ATM inhibition. We observed
that PFKFB3 protein levels are not affected by KAN0438757 or
ATM inhibitor treatments nor do we detect any protein
modiﬁcations on PFKFB3 upon IR (Fig. 4e). Thus, the IR-
induced accumulation of PFKFB3 (Figs. 1 and 2) is likely due to
recruitment and not due to a global increase in PFKFB3 protein
levels. Consistent with PFKFB3 being downstream of MRN,
ATM, γH2AX, and MDC1 (Fig. 1), KAN0438757 did not affect
IR-induced phosphorylation of ATM, H2AX, or KAP-1 (Fig. 4e).
RAD51 expression levels were assessed in order to conﬁrm that
the KAN0438757-dependent decrease in RAD51 recruitment in
Fig. 4a was not due to decreased RAD51 protein levels (Fig. 4e).
We next performed clonogenic survival assays, in which U2OS
cells pre-treated with KAN0438757 prior to IR displayed a dose-
dependent radiosensitization to form colonies 10 days post
treatments (Fig. 4f). To determine if the decreased clonogenic
survival upon inhibition was due to lack of recruitment of
RAD51, we overexpressed RAD51 prior to treatment with
KAN0438757 and IR. Notably, RAD51 overexpression rescued
the clonogenic survival at the IC50 concentration of KAN0438757
in the assay (Supplementary Figure 8d), suggesting a loss of HR
by KAN0438757 contributes to the toxicity.
Since PFKFB3 protein levels are increased in cancer versus
normal matched tissues13, we next compared the effect of
KAN0438757 in isogenic immortalized and transformed cells. BJ
TERT (hTERT immortalized normal ﬁbroblasts) and BJ RAS
were treated with KAN0438757 or vehicle for 24 h and then
subjected to IR or left untreated. The inhibitors were washed out
72 h later and colonies were counted 4 days (BJ RAS) or 7 days
(BJ TERT) later. The BJ RAS cells displayed decreased clonogenic
survival, in a dose-dependent manner, upon KAN0438757
treatment at concentrations that only marginally affected BJ
TERT both in conditions with and without IR (Fig. 4g, left graph).
This indicates tolerability to KAN0438757 by normal cells at
concentrations enhancing radiosensitivity and disrupting survival
in cancer cells. In comparison, inhibition of ATM and ATR in
combination with IR resulted in a 10% or less survival of the non-
transformed BJ TERT cells, while being equally effective as
KAN0438757 at inhibiting survival of the transformed BJ RAS
cells (Fig. 4g, middle and right graphs). These data suggest that
PFKFB3 inhibition induces DNA repair deﬁciency speciﬁcally in
transformed cells, while being expendable to non-transformed
cells in contrast to ATM and ATR. Altogether, our data show that
PFKFB3 kinase activity is involved in the recruitment of DNA
repair factors upon IR, successful DNA repair, recovery from IR-
induced cell cycle arrest, and long-term survival of transformed
cells.
PFKFB3 promotes nucleotide incorporation during DNA
repair. Given the role of PFKFB3 in the generation of deoxyr-
ibonucleotide triphosphates (dNTPs), we hypothesized a role of
PFKFB3 in HR-dependent repair synthesis. To test this directly,
the kinetics of incorporation of deoxynucleotides during DNA
repair was investigated by assessing thymidine analogue 5-ethy-
nyl-2′-deoxyuridine (EdU) incorporation into DNA in the G2/M
phase upon IR. Notably, treatment with KAN0438757 prior to IR
impaired the IR-induced increase in the EdU-positive cell
population in the G2/M phase (Fig. 5a), suggesting the involve-
ment of the kinase activity of PFKFB3 in deoxynucleotide
incorporation during HR-dependent repair synthesis. In this
analysis, we excluded cells in the S phase to disregard contribu-
tions from EdU incorporation during replication rather than as a
result of DNA repair. The possible reasons why PFKFB3 inhibited
cells fail to incorporate deoxynucleotides during DNA repair
could be either that PFKFB3 supports localized dNTP supply via
its role in glycolysis or that it recruits a factor needed for dNTP
production. Given the established role of PFKFB3 in supporting
glycolysis including its diversion towards the synthesis of the
nucleotide precursor PRPP, it is easy to envision a potential role
of the IR-induced recruitment of PFKFB3 in localized dNTP
production via its role in glycolysis. There is an obvious issue with
this hypothesis, as glycolysis normally takes place in the cyto-
plasm where the F-2,6-P2 activator is well established as a positive
allosteric regulator of PFK-1, suggesting this is unlikely. The
RRM2 subunit of the RNR localizes to the nuclei in response to
IR to ensure local dNTP production for repair DNA
synthesis39,40, thus we hypothesized that PFKFB3 may support
the supply of dNTPs for DSB repair via recruitment of RRM2. To
test this, we assayed to what extent modulation of PFKFB3
activity impacts RRM2 recruitment upon IR. Both PFKFB3 and
RRM2 were recruited into repair foci in an ATM-, but not ATR-,
dependent manner upon IR (Fig. 5b). Importantly, the enzymes
co-localized and this was disrupted upon pre-treatment with
KAN0438757 or an ATM inhibitor prior to IR (Fig. 5b).
Knockdown of PFKFB3 with two different oligos also abolished
the IR-induced recruitment of RRM2 as well as the IR-induced
co-localization between PFKFB3 and RRM2 (Fig. 5c). To
Fig. 4 PFKFB3 kinase activity is needed for effective DNA repair. a Confocal analysis of IR-induced foci of RAD51 or RPA32 in U2OS cells following
treatment with DMSO or 10 μM KAN757 (6 h), subjected to IR (6 Gy, 2 h recovery), or left untreated. Shown is a representative experiment of n= 3. Scale
bar, 10 μm. To the right, scatter dot plot representing the intensity of the ﬂuorescent levels of RAD51 or RPA32 as assessed by quantifying nuclear intensity
using CellProﬁler, n > 500 cells/treatment. b Bar chart showing the percentage of foci per nuclei in (a) as quantiﬁed using CellProﬁler. Data are displayed
as means ± SEM, **P < 0.01, *P < 0.05; Student’s t-test. c HR activity after treatment of U2OS DR-GFP cells with indicated inhibitors as assessed by FACS
analysis. DMSO treated cells are taken as reference cells (100% activity). Data are displayed as means ± SEM, n= 3. ***P < 0.001; Student’s t-test. d DNA
damage levels were assessed using γH2AX staining, U2OS cells were treated with DMSO or KAN0438757 for 6 h, subjected to IR (6 Gy, 2 h, and 24 h
recovery), and immunostained for γH2AX. Scale bar, 10 μm. Right panel, quantiﬁcation of average γH2AX IRIF per cell and percentage of γH2AX positive
cells (>10 γH2AX foci per cell) using CellProﬁler. Data are displayed as means, n > 500 cells/treatment. **P < 0.01; one-way ANOVA analysis. e U2OS cells
were treated with DMSO, 10 μM of KAN757 or 10 μM of KU55933 (ATM inhibitor) for 24 h, exposed to IR (6, 10, and 15 Gy) and harvested at the indicated
time points. Whole cell extracts were prepared and protein levels were analyzed by western blot using indicated antibodies, β-actin was used as loading
control. Shown is a representative experiment of n= 3. f Colony formation of U2OS cells upon PFKFB3 inhibition. U2OS cells were treated with DMSO or
10 μM KAN757 for 3 days, then exposed to indicated doses of IR or left untreated, inhibitors were washed out and 5 days later colonies were stained with
4% methylene blue-MeOH and counted. Data are displayed as means ± SEM, n= 3. **P < 0.01, ***P < 0.001; one-way ANOVA analysis. g Colony
formation upon PFKFB3 inhibition in transformed and non-transformed cells. BJ TERT or RAS cells were treated with vehicle (DMSO) or indicated
concentrations of inhibitors for 3 days, exposed to IR (2 Gy), or left untreated. Inhibitors were washed out 24 h post IR and 4 days (RAS) or 7 days (TERT)
later colonies were stained with 4% methylene blue-MeOH and counted. Data are displayed as means ± SEM, n > 3. **P < 0.01, ***P < 0.001; one-way
ANOVA analysis. KAN757= KAN0438757
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investigate a possible physical interaction between PFKFB3 and
RRM2, we next performed co-immunoprecipitation experiments.
Consistent with our observation that PFKFB3 and RRM2 co-
localize upon IR, FLAG-PFKFB3 was brought down by RRM2
antibodies at 2 h post-IR (Fig. 5d), while we could not detect any
interaction between FLAG-PFKFB3 and RRM2 in non-IR con-
ditions (Supplementary Figure 9).
To evaluate the contribution of RRM2 to functional HR, we
measured HR activity in the DR-GFP assay upon treatment with
RRM2 siRNA. Knockdown of RRM2 reduced the HR activity to
approximately 10% (Fig. 5e, Supplementary Figure 2g), similar to
what was observed upon PFKFB3 inhibition. Thus, the block in
HR repair upon PFKFB3 inhibition could be due to insufﬁcient
nucleotide availability as a result of impaired recruitment of
RRM2, suggesting the involvement of PFKFB3 activity in
nucleotide incorporation during repair synthesis.
PFKFB3 supports dNTP supply in DNA synthesis. Depletion of
dNTP pools through inhibition of the RNR is well known to stall
replication forks that eventually collapse and generates DSBs41.
Thus we sought to determine whether inhibition of PFKFB3 also
in the absence of IR would modulate deoxynucleotide incor-
poration in RNR-dependent processes. Indeed, we observed
decreased EdU intensity per cell in the EdU-positive cell popu-
lation upon KAN0438757 treatment (Fig. 6a), indicative of
impaired DNA replication. Notably, the decrease in EdU intensity
upon PFKFB3 inhibition was similar in magnitude to that
observed for inhibition of replication and induction of replication
stress by hydroxyurea (HU) (Fig. 6a). To further investigate
whether DNA replication is limited by insufﬁcient salvage of
deoxynucleotides in cells treated with PFKFB3 inhibitor, we
performed DNA labeling studies to directly determine nucleotide
incorporation into DNA over time by using the DNA ﬁber
technique. KAN0438757 treatment severely decreased incor-
poration of 5-chloro-2′-deoxyuridine (CldU) and 5-iodo-2′-
deoxyuridine (IdU) in U2OS cells (Fig. 6b), thus the speed of the
replication fork is impaired upon PFKFB3 inhibition. Notably,
nucleoside supplementation during the duration of KAN0438757
treatment restored the replication fork speed (Fig. 6b). To further
conﬁrm a role for PFKFB3 in intracellular dNTP supply, we next
measured the dNTP pools upon KAN0438757 treatment of U2OS
cells at the time points for the decreased EdU intensity (4 h) as
well as for the inhibition of replication fork speed (24 h).
KAN0438757 treatment resulted in a 50–75% decrease for all four
dNTPs (Fig. 6c). This together with the nucleoside rescue of fork
speed suggests that reduced dNTP pools could explain the
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Fig. 6 Nucleoside supplementation restores proliferation of PFKFB3 inhibited cells. a Effects on DNA synthesis of U2OS cells treated with DMSO or
indicated concentrations of KAN757 (4 h), pulsed with 10 μM EdU for 40min, followed by ﬁxation, ﬂuorescent labeling, and quantiﬁcation in CellProﬁler,
>100 cells were analyzed per condition, n= 2. **P < 0.01; one-way ANOVA analysis. b Schematic representation of the DNA ﬁber assay and representative
images of DNA strands incorporating CldU (red) and IdU (green) from U2OS cells that have received treatment with 10 μM KAN757 supplemented with or
without 30 μM nucleosides. Graphs show the distribution of average fork speed and calculated mean fork speed for the indicated treatments (n > 100 forks
per condition). Data are displayed as means ± SEM, n= 3. ***P < 0.001; Student’s t-test. c dNTP measurements of U2OS cells treated as indicated. Relative
levels of dNTPs were calculated relative to DMSO. Data are displayed as mean ± SEM, n= 2. *P < 0.05; Student’s t-test. d Metabolic rescue of the
proliferation of U2OS cells following 10 nM siControl or siPFKFB3 treatments and supplementation with or without 30 μM nucleosides was assessed by
DAPI staining and counting nuclei using CellProﬁler. siControl cells are set as reference cells. Data are displayed as means ± SEM, n= 2. *P < 0.05; one-way
ANOVA analysis. e Scatter dot plot representing the nuclear intensity of the ﬂuorescence levels of RPA32 in U2OS cells following treatment with DMSO or
indicated inhibitors as quantiﬁed using CellProﬁler. Lines represent mean ﬂuorescence, n > 500 cells/treatment. f Representative immunoblots (of n= 2) of
U2OS cells treated with DMSO, KAN757 (10, 30 µM) and/or HU (2mM) for indicated time points. Bands correspond to whole cell extracts, β-actin was
used as loading control. g Bar charts representing relative levels of phosphorylated ATR and ATM, p53 and γH2AX in (f). Densitometric analysis was
performed using Image StudioTM Lite Software. Signal intensity data were normalized against β-actin and then normalized to DMSO 24 h. Data are
displayed as means ± SD, n= 2 independent experiments. KAN757= KAN0438757
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decreased fork progression upon PFKFB3 inhibition. To com-
plement the PFKFB3 inhibitor data, we supplemented cells with
nucleosides at the timepoint for siRNA transfections and
observed restored proliferation of the PFKFB3 knockdown cells
(Fig. 6d).
We next investigated if the stalled forks upon KAN0438757
treatment collapse as measured by quantiﬁcation of ssDNA
coated by RPA. In contrast to HU, PFKFB3 inhibition did not
induce RPA-coated ssDNA, p53 induction, or phosphorylation of
either ATR, ATM, Chk1, or H2AX (Fig. 6e–g). Combined
inhibition of PFKFB3 and RNR blocked the HU-dependent
induction of phosphorylated ATR, Chk1, and ATM, increase in
p53 levels as well as an increase in γH2AX levels (Fig. 6f, g), in
line with PFKFB3 activity being upstream of RRM2 recruitment
(Fig. 5b). Our data suggests that PFKFB3 inhibition results in the
insufﬁcient supply of nucleotides during replication, resulting in
stalled replication forks without causing replication fork collapse
or checkpoint activation.
Discussion
Targeting a metabolic enzyme that is only needed for functional
DDR in cancer cells and not in normal cells could be used to
selectively impair survival of cancer cells and avoid toxicity to
non-cancer cells. In this study, we identify PFKFB3 as a novel
component of the DNA damage response and repair, demon-
strate PFKFB3 activity as essential for DNA replication as well as
generate a selective PFKFB3 inhibitor KAN0438757.
Our data strongly support a model where PFKFB3 is recruited
rapidly upon IR through the MRN complex-ATM-γH2AX-
MDC1 into nuclear foci at DNA damage and repair sites. Con-
sequently, PFKFB3 is required for recruitment of the downstream
HR repair factors BRCA1, RPA, and RAD51 as well as mobili-
zation of the RRM2 subunit of RNR to sites of DNA damage
(Fig. 7). Inhibition of PFKFB3, by siRNA silencing or
KAN0438757, blocks HR activity and disrupts deoxynucleotide
incorporation during DNA repair. This result in unrepaired
DSBs, consistent with high levels of residual γH2AX foci, delayed
recovery from IR-induced G2/M phase arrest and induces
radiosensitization.
The intracellular levels of dNTPs are under tight control and
increase 20-fold during the replicative S phase and upon DNA
damage42. Consequently, imbalanced dNTP pools result in
impaired replication fork speed and defective DNA repair43,44.
Thus, a signiﬁcant contribution to the impairment in DNA repair
and replication upon PFKFB3 inhibition is likely coming from
defective nucleotide incorporation; supported by dNTP mea-
surements, IR-induced EdU incorporation studies in the G2/M
phase of the cell cycle, as well as nucleoside rescue experiments.
The control of the dNTP pools is exerted mainly via the RNR
enzyme, with the RRM2 subunit being recruited to DNA damage
sites39,40,45. Consistent with this, we identiﬁed the interaction
between PFKFB3 and RRM2 upon IR as well as co-localization in
a kinase-dependent manner upon induction of DSBs. The beneﬁt
of this recruitment could be to compartmentalize dNTPs directly
at the DNA lesions to allow a high local dNTP concentration
upon DNA repair. However, the limitation in determining dNTP
concentrations site speciﬁcally in the nucleus makes it difﬁcult to
assess. Therefore we here assessed IR-induced EdU incorporation
in the G2/M phase upon IR as well as total dNTP levels upon
PFKFB3 inhibition both of which decreased upon PKFB3 inhi-
bition. Our ﬁndings suggest that via recruitment of RRM2,
PFKFB3 ensures local dNTP supply at DSB sites in a timely
manner to coordinate the efﬁcient supply of dNTPs with the
recruitment of HR factors upon repair (Fig. 7).
Our data places PFKFB3 downstream in the IR-induced ATM
signaling pathway (Fig. 7). Previously it has been reported that
ATM-defective patients are insulin resistant and display
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Fig. 7 PFKFB3 mediates ATM-dependent break-induced dNTP supply. MRE-ATM-γH2AX-MDC1 signaling recruits PFKFB3 into nuclear foci, within the
DNA damage response upon IR. PFKFB3 activity is required for subsequent recruitment of the RRM2 subunit of ribonucleotide reductase to sites of DNA
damage to potentially generate a local dNTP pool. Inhibition of PFKFB3 activity impairs IR-induced repair synthesis, homologous recombination, and
replication fork progression, which is restored by nucleoside supplementation
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symptoms of altered glucose metabolism46. Consistent with this,
proteomic proﬁling of ATM proﬁcient versus deﬁcient lympho-
blastoid cells revealed an altered metabolism as well as enrich-
ment of proteins involved in glycolysis/gluconeogenesis pathway
and carbohydrate metabolism47. The advantage of ATM pushing
metabolic alterations could be to provide precursors such as
nucleotides and amino acids for biosynthetic reactions to rapidly
fuel cells upon DNA damage to promote repair, for instance
providing the cell with ATP.
Although it is easy to anticipate that a possible PFKFB iso-
form switch during cancer transformation to PFKFB3 would
give the advantage of a high glycolytic ﬂux in malignant cells
due to the enzyme’s high kinase to phosphatase ratio, nuclear
PFKFB3 has been shown to drive proliferation dependent on its
enzymatic function without increasing the overall cellular gly-
colysis22. Notably, no differential glucose consumption can be
measured in vitro upon IR exposure48. Although the glycolytic
enzyme phosphoglycerate mutase 1 (PGAM1) has been impli-
cated in supporting HR and modulate the dNTP pool via its
enzymatic activity, PGAM1 does not (and no glycolytic enzyme
has to our knowledge been shown to) relocalize into repair foci
in the nuclei upon DSB induction to support HR49. Thus the
PFKFB3-mediated regulation of DNA repair is most likely not
due to a global upregulation of glycolysis upon IR, suggesting a
possible localized enzymatic function of PFKFB3 to support
DNA repair and replication in the nucleus, likely by
providing local dNTPs. However, a limitation of this study is
that we were unable to measure synthesis of fructose-2,6-
bisphosphate at DSB repair sites. To determine the extent to
which local fructose-2,6-bisphosphate contributes to PFKFB3-
mediated DNA repair, the focus of future research should be
directed towards the development of sensitive tools capable of
detecting fructose-2,6-bisphosphate directly at DNA repair
sites.
The PFKFB3 isoform is favored in malignant cells with its
enzymatic activity following its expression, thus its enzymatic
activities represent an attractive anti-cancer drug target. Here, we
report a radiosensitizing effect upon PFKBF3 reduction and
inhibition, as demonstrated by suppression of HR and a high
frequency of unrepaired DNA damage, as measured by assessing
γH2AX levels. Consistent with its expression proﬁle, the radio-
sensitizing effect upon PFKFB3 inhibition seems selective to
cancer cells as survival of immortalized cells was only marginally
affected at the doses affecting the survival of cancer cells upon IR.
In the clinic, the radiation dose set to kill cancer cells in patients is
limited with respect to normal tissue tolerance, thus our ﬁndings
suggest PFKFB3 inhibition as an attractive approach to poten-
tially achieve cancer-speciﬁc DNA repair deﬁciency upon radia-
tion therapy. Several inhibitors targeting enzymes involved in
DNA repair are under clinical evaluation50; with our data in mind
demonstrating a tight association between PFKFB3 activity and
successful DNA repair, it is easy to envision that combining such
inhibitors with our PFKFB3 inhibitor could improve the ther-
apeutic index further.
Methods
Cells and culture conditions. U2OS, PANC-1, NUGC-3, SW620, and MIA PaCa-
2 were obtained from American Type Culture Collection (ATCC, Manassas, VA,
USA). The BJ-hTER and BJ-RasV12 cell were provided by W. Hahn (Dana-Farber
Cancer Institute) and the DR-GFP U2OS cells were provided by M. Jasin (Mem-
orial Sloan Kettering Cancer Center). U2OS, DR-GFP U2OS, BJ-hTERT, and BJ-
RasV12 cells were maintained in Dulbecco’s modiﬁed Eagle medium (DMEM)
supplemented with 5% fetal bovine serum (FBS, Life Technologies/ThermoFisher
Scientiﬁc), and penicillin–streptomycin antibiotics (50 U/mL). MIA PaCa-2,
PANC1, SW620, and SW480 were grown in DMEM (Lonza Biosciences), with 10%
FBS (Life Technologies/ThermoFisher Scientiﬁc). Cells were grown at 37 °C in 5%
CO2 humidiﬁed incubators.
Clonogenic survival. U2OS cells were transfected with indicated siRNAs and 24 h
later exposed to IR (2 Gy) or left untreated and allowed to recover for 4 h. One-
hundred U2OS cells were then seeded into 6-well plates and after 10 days colonies
were ﬁxed and stained with 4% methylene blue (Sigma Aldrich) in methanol. BJ
TERT (500 cells), BJ RAS (200 cells), or U2OS (200 cells) were seeded into 6-well
plates 24 h prior to treatment with inhibitors as indicated or vehicle for 24 h and
then subjected to IR (2 Gy). The inhibitors were washed out 72 h later and colonies
were ﬁxed 4 days (BJ RAS) or 7 days (BJ TERT) later with 4% methylene blue in
methanol.
For RAD51 rescue experiments, 1 × 106 BJ RAS cells were seeded in 100 mm
dishes and transfected the next day with 5 μg empty vector or RAD51-GFP
plasmid. After 24 h, 200 cells were seeded on 6-well plates, at the time of seeding
equal amounts of cells were collected from RAD51 and empty vector-transfected
cells, and lysed and subjected to western blot to conﬁrm the overexpression of
RAD51. Twenty-four hours post-seeding, cells were treated with inhibitors as
indicated or vehicle for 24 h and then exposed to IR (2 Gy). The inhibitors were
washed out 72 h later and colonies were ﬁxed 12 days later with 4% methylene blue
in methanol. Colonies were counted manually.
Ionizing radiation. γ-Irradiation was performed with a 137Cs source (Scandi-
tronix) at the Karolinska Institutet, Stockholm, at a photon dose rate of 0.5 Gy/min.
Dosimetry was done with an ionization chamber as well as with ferro-sulphate. X-
ray high-intensity radiation was performed with an X-RAD 225 XL irradiator
(Precision X-Ray), courtesy of the Farnebo lab (Cancer Center Karolinska).
Immunoﬂuorescence microscopy. Cells were grown on sterilized coverslips and
ﬁxed with 4% paraformaldehyde (PFA) (Santa Cruz) and 2% sucrose (Sigma
Aldrich) for 15 min at room temperature. They were then permeabilized with 0.2%
NP-40 (Thermo Scientiﬁc) for 10 min at room temperature followed by 30 min of
blocking in blocking buffer (2 or 3% BSA, 5% glycerol, 0.1% Tween 20 (Sigma
Aldrich)). Coverslips were subsequently incubated for 1, 2, or 24 h in primary
antibody and 40 min in secondary antibody diluted in blocking buffer, DNA was
stained with DAPI for 10 min. The coverslips were mounted with Prolonged Gold
mounting medium (Invitrogen). Images were acquired with a Zeiss LSM 780
microscope using a 40× or 63× oil immersion lens and processed in ImageJ and
CellProﬁler.
In situ cell fractionation. To visualize PFKFB3, RPA32, RAD51, BRCA1, 53BP1,
and RRM2 IRIF, the cells were ﬁrst washed with PBS and then incubated for 5 min
at room temperature with cytoskeleton (CSK) buffer containing 10 mM PIPES pH
7.0 (Sigma Aldrich), 100 mM NaCl (EMD Millipore), 300 mM sucrose (Sigma
Aldrich), 3 mM MgCl2 (Sigma Aldrich), and 0.7% Triton X-100 (Sigma Aldrich).
After these treatments, the cells were washed once again with PBS and then ﬁxed in
4% PFA with 2% sucrose.
Western blot. Cells were lysed on ice using the NP-40 lysis buffer (50 mM
Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40) supplemented with protease and
phosphatase inhibitors (Roche). Protein lysates were quantiﬁed using the Pierce
BCA Protein Assay Kit (ThermoFisher Scientiﬁc), equal amounts of protein were
heated to 70 °C in NuPAGE LDS Sample Buffer (ThermoFisher Scientiﬁc) and
loaded on Mini-PROTEAN® precast gels (Bio-Rad) and run at 120 V. Transfer to
nitrocellulose membrane (Bio-Rad) was done using Trans-Blot Turbo Transfer
System (Bio-Rad). Membranes were blocked for 1 h at RT in blocking buffer (5%
BSA, 0.1% Tween-20 in PBS, or 1:1 Li-Cor Blocking Buffer/TBS+ 0.05% Tween-20
(TBS-T)), incubated with primary antibodies overnight at 4 °C and then incubated
1 h at RT with secondary antibodies diluted at 1:10,000 in 1:1 Li-Cor blocking
buffer/TBS-T. Bands were visualized with an Odyssey Fc Imager and analyzed with
ImageJ or with Image Studio Software (Li-Cor Biosciences). Uncropped western
blots are shown in Supplementary Figure 10, 11, 12, 13, 14, 15, 16.
Immunoprecipitations. U2OS cells were seeded into 6-well plates 24 h before
transfection with 1 μg of indicated plasmids, after 24 h post-transfection cells were
exposed to IR (6 Gy) or left untreated. Two hours post-IR, cells were assayed for
protein interactions as previously described51. The supernatant was immunopre-
cipitated with RRM2 antibody (Santa Cruz, catalog no. sc10844) or IgG overnight
at 4 °C. The following day, 40 μl Protein G slurry was added for 4 h at 4 °C, then
protein complexes were washed four times in 500 μl lysis buffer, and lysed in 60 μl
NuPAGE LDS Sample Buffer (ThermoFisher Scientiﬁc). Protein complexes were
subjected to 10% SDS-PAGE followed by western blot analysis with FLAG anti-
body (Sigma Aldrich, catalog no. F3165).
Antibodies. The following antibodies were used in immunoﬂuorescence and
Western blots: rabbit anti-PFKFB3 (Proteintech, cat. no. 13763-1-AP, WB 1:500, IF
1:100), rabbit anti-PFKFB3 (Cell Signaling, cat. no. 13123, 1:500), rabbit anti-ATM
p-Ser-1981 (Abcam, cat. no. ab81292, 1:500), mouse anti-ATM (Santa Cruz, cat.
no. sc-23921, 1:500), rabbit anti-ATR p-Ser-428 (Cell Signaling, cat. no. 2853S,
1:500), rabbit anti-DNA-PK p-Ser-2056 (Abcam, cat. no. ab18192, 1:500), mouse
anti-Flag (Sigma Aldrich, cat. no. F3165, 1:500), rabbit anti-KAP1 p-Ser-824
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(Bethyl Laboratories, cat. no. A300-767A, 1:500), goat anti-KAP1 (Bethyl
Laboratories, cat. no. A303-838A, 1:500), mouse anti-γ-H2AX (Millipore, cat. no.
05-636, WB 1:1000, IF 1:500), rabbit anti-γ-H2AX (Cell Signaling, cat. no. 2577 S,
1:1000), rabbit anti-Histone H2A (Abcam, cat. no. ab18255, 1:500), rabbit anti-
Histone H3 (Abcam, cat. no. ab1791, 1:2000), rabbit anti-Mre11 (Novus Biologi-
cals, cat. no. NB100-142, 1:500), rabbit anti-Nbs1 (Novus Biologicals, cat. no.
NB100-143, 1:500), rabbit anti-RAD51 (Santa Cruz, cat. no. sc-8349, 1:500), mouse
anti-RAD51 (Abcam, cat. no. ab213, 1:500), rabbit anti-RPA p-Ser-33 (Novus
Biologicals, cat. no. NB100-544, 1:500), rat anti-RPA2/32 (Cell Signaling, cat. no.
2208S, 1:100), rabbit anti-53BP1 (Novus Biologicals, cat. no. NB100-904, 1:500),
mouse anti-53BP1 (Abcam, cat. no. ab36823, 1:100), mouse anti-BRCA1 (Santa
Cruz, cat. no. sc-6954, 1:100), goat anti-RRM2 (Santa Cruz, cat. no. sc-10844,
1:500), mouse anti-RRM2 (Abcam, cat. no. ab57653, 1:500), mouse anti-RRM2
(Sigma Aldrich, cat. no. WH0006241M1, WB 1:500, IF 1:100), mouse anti-p53
(Santa Cruz, cat. no. sc-126, 1:500), rabbit anti-Chk1 p-Ser-345 (Cell Signaling, cat.
no. 2341S, 1:250), rabbit anti-MDC1 (Abcam, cat. no. ab11169, 1:500), mouse anti-
SOD-1 (Santa Cruz, cat. no. sc-17767, 1:1000), rabbit anti-GFP (Santa Cruz, cat.
no. sc-8334, 1:1000), mouse anti-β-actin (Abcam, cat. no. ab6276, 1:10,000), rabbit
anti-α-tubulin (Abcam, cat. no. ab18251, 1:1000), rabbit anti-β-tubulin (Abcam,
cat. no. ab6046, 1:1000), and goat anti-vinculin (Santa Cruz, cat. no. sc-7649,
1:1000).
The secondary antibodies for confocal were: goat anti-rabbit Alexa Fluor 488
(Invitrogen, cat. no. A11008, 1:500), goat anti-mouse Alexa Fluor 488 (Invitrogen,
cat. no. A11029, 1:500), donkey anti-mouse Alexa Fluor 488 (Invitrogen, cat. no. A-
21202, 1:500), goat anti-rat Alexa Fluor 555 (Invitrogen, cat. no. A-21434, 1:500),
donkey anti-goat Alexa Fluor 555 (Invitrogen, cat. no. A-21432, 1:500), goat anti-
rat Alexa Flour 568 (Invitrogen, cat. no. A-11077, 1:500), donkey anti-goat Alexa
Fluor 633 (Invitrogen, cat. no. A-21082, 1:500), donkey anti-mouse Alexa Fluor
647 (Invitrogen, cat. no. A-3157, 1:500).
The secondary antibodies for Western blot were: donkey anti-mouse IgG IRDye
680RD (925-68072, 1:5000), goat anti-rabbit IgG IRDye 800CW (925-32211,
1:5000), donkey anti-rabbit IRDye 800CW (926-32213, 1:5000), donkey anti-
mouse IRDye 800CW (926-32212, 1:5000), and donkey anti-goat IRDye 800CW
(925-32214, 1:5000) from Li-Cor Biosciences.
EdU labeling of cultured cells. U2OS cells were seeded on sterilized slides and
treated with 10 or 30 μM of 757 for 6 h, or 2 mM of hydroxyurea (HU) for 3 h
(DMSO was used as control vehicle). Last 40 min of treatment, 10 μM of the
thymidine analogue 5-ethynyl-2′-deoxyuridine (EdU) (Sigma Aldrich, catalog no.
1T511285) was added; cells were washed with PBS and then ﬁxed with paraf-
ormaldehyde 4% and sucrose 2%. For the detection of incorporated EdU, the Click
IT reaction was performed in accordance with the supplier’s recommendations
(Life Technologies/ThermoFisher Scientiﬁc). Images were acquired with a Zeiss
LSM 780 microscope using a 40× oil immersion lens and processed in ImageJ and
CellProﬁler (version 2.2.0).
siRNA transfections. The siRNA oligonucleotides used were siPFKFB3#1
(Ambion, 4390824, ID:s10357), siPFKFB3#2 (Ambion, 4390824, ID:s10358),
siH2AX (Qiagen, SI00032844), siMDC1 (Dharmacon, L-003506-00-0005), siRRM2
(Dharmacon, L-010379-00-0005), siRAD51 (Qiagen, SI02663682), and siControl
(Dharmacon). siRNA (10 nM) was transfected into cells using INTERFERin
(Polyplus transfections) transfection reagent in accordance with the supplier’s
recommendations.
Plasmid transfections. The I-SceI plasmid was kindly provided by M. Jasin
(Memorial Sloan Kettering Cancer Center), RAD51-GFP was a kind gift from F.
Dantzer (Institut de Recherche de l’Ecole de Biotechnologie de Strasbourg), and
empty vector and FLAG-PFKFB3 has previously been described22. Plasmids were
transfected into cells using JetPEI or JetPRIME (Polyplus transfections) transfec-
tion reagents in accordance with the supplier’s recommendations.
Treatment with small-molecule inhibitors and metabolites. 3-PO, ATM
(KU5593352), and DNA-PK (NU744153) inhibitors were obtained from TOCRIS
bioscience. The ATR inhibitor (VE-82154) was obtained from Axon MedChem
(catalog no. Axon 1893) and Hydroxyurea (HU) and the MRN complex inhibitor
Mirin (catalog no. M9948) were purchased from Sigma Aldrich. Where appro-
priate, 10 μM ATM inhibitor, 2 μM DNA-PK inhibitor, 2.5 μM ATR inhibitor, and
2 mM HU were added to the culture medium 6 h prior to IR. For experiments
using Mirin, 300 μM was added to the culture medium 2 h prior to IR. A 30 mM
nucleoside mix containing adenosine, cytidine, guanosine, and uridine (Sigma
Aldrich) was prepared fresh before each experiment and added to a ﬁnal con-
centration of 30 μM at the same time as siRNA transfections or inhibitor
treatments.
Flow cytometry. For cell cycle analysis, cells were treated or transfected with
siRNA as described and harvested at the indicated time points with trypsin. For
studies using IR, cells were exposed to IR with 2 Gy, and harvested at the indicated
time points with trypsin. The cells were washed in PBS and ﬁxed with 70% ethanol
in PBS at 4 °C for 1 h and then stored at −20 °C until staining. Ethanol was
removed by centrifugation and cells were then washed in PBS before staining DNA
with propidium iodide (PI) solution containing 40 μg/mL PI, 100 μg/mL RNase A,
and 0.1% Triton X-100 (Sigma Aldrich). Cells were analyzed by ﬂow cytometry on
a FACS Navios (Beckman Coulter) using Kaluza software.
Method for measurement of intracellular dNTP. HIV-1 RT-based dNTP assay55
was used to quantify dNTP levels in U2OS cells upon indicated treatment and time
points. Brieﬂy, cells were trypsinized and counted before dNTPs extraction by 60%
methanol solution, the dried dNTP samples were resuspended with water, and then
RT-based primer extension reaction was performed to determine the amounts of
dNTPs. Obtained dNTP amounts were normalized to 1 × 106 cells, and dNTP
levels were related to control treatment with DMSO.
DR-GFP (HR) assays. 5 × 104 U2OS (DR-GFP) cells were seeded into 12-well
plates, 24 h later cells were treated with the indicated siRNAs or inhibitors and, 24
h later, transfected with 150 ng of an I-SceI vector using JetPEI or JetPRIME
(Polyplus transfections). The next day, the medium was changed; 24 h after this,
cells were harvested by trypsinization and washed with PBS, and the GFP signal
was measured by ﬂow cytometry on a FACS Navios (as described above). The
frequency of repair in cells treated with inhibitors or transfected with the various
siRNAs was calculated relative to cells treated with DMSO or transfected with
control siRNA.
DNA ﬁber assay. 1 × 105 cells were seeded into 6-well plates, 24 h later cells were
treated with the indicated inhibitors or nucleosides, and 24 h later DNA was
labeled with 25 μM CldU (Sigma, C6891) in pre-warmed DMEM for 20 min,
washed and then labeled with 250 μM IdU (Sigma I7125) in pre-warmed DMEM
for 20 min, before harvesting by scraping in cold PBS. Harvested cells were diluted
to 1 × 106 cells/mL, spreading and staining was performed as described previously
described56. Fluorescence images were captured using a Zeiss LSM 780 inverted
confocal microscope using a 63 × 1.4 oil immersion objective, excitation wave-
lengths of 488 and 555 nm, and analyzed using the ImageJ software. At least 300
unidirectional forks labeled with both CldU and IdU were measured for every
condition.
CETSA. U2OS cells in exponential growth rate were treated with indicated inhi-
bitors at a concentration of 10 μM or DMSO for 6, 24, or 72 h and then harvested
using trypsin, upon detachment trypsinization was inhibited by addition of cell
media and cells spun down at 200 × g for 10 min at 4 °C. The pellet was resus-
pended in TBS (50 mM Tris–HCl (pH 7.5) and 150 mM NaCl) supplemented with
protease inhibitors (Roche), cells were lysed by a freeze–thaw circle three times at
−80 °C for 3 min and then 37 °C for 3 min. Debris was removed by centrifugation
at 16,000 × g for 20 min at 4 °C, cell lysates were aliquoted and heated to indicated
temperatures for 3 min. Insoluble proteins were then removed by centrifugation at
16,000 × g at 4 °C for 20 min, supernatant was transferred to new tubes and protein
concentration was determined using BCA assay (Pierce). Western blot was per-
formed according to standard procedures.
Gene expression proﬁling. Expression proﬁling of PFKFB3 mRNA levels (GEO
accession number GSE13280) in mononuclear cells isolated from bone marrow
samples from pediatric B-precursor ALL patients responsive to radiotherapy before
(n= 11) and after (n= 11) radiotherapy, pediatric ALL patients resistant to
radiotherapy before (n= 11) and after (n= 11) radiotherapy. Tukey’s multiple
comparisons test was used to calculate signiﬁcance (GraphPad Prism).
Statistical analysis. Statistical signiﬁcance was determined via two-tailed Stu-
dent’s t-test or ANOVA using GraphPad Prism 7 or Excel. The results originate
from at least two independent experiments and are presented as means ± standard
error of the mean or standard deviation. Signiﬁcance values were set at *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001.
Chemical synthesis. NMR spectra were recorded on a Varian Inova 600 equipped
with a triple resonance cold probe or a triple resonance probe. Purity was deter-
mined by analytical HPLC (Agilent Series 1100 system) using two different col-
umns (ACE C8 (3 µm, 3.0 × 50 mm) column with 0.1% TFA in MilliQ water/
MeCN as mobile phase and XTerra (3.5 µm, 3.0 × 50 mm) column with 10 mM
pH10 NH4HCO3/MeCN as mobile phase). Electrospray mass spectrometry
(ES-MS), used to support correct molecular weight identity for synthesized com-
pounds, was performed using an Agilent 1100 Series Liquid Chromatograph/Mass
Selective Detector (MSD) to obtain the pseudo molecular [M+H]+ ion of the
target molecules. The compounds were named using the software ACD Labs.
Synthesis of 4-{[(5′-Fluoro-2′-hydroxybiphenyl-3-yl)sulfonyl]amino}-2-
hydroxybenzoic acid (KAN0438241): A mixture of methyl 4-{[(3-bromophenyl)
sulfonyl]amino}-2-hydroxybenzoate (1.05 g, 2.7 mmol), 5-ﬂuoro-2-
hydroxyphenylboronic acid (0.47 g, 3.0 mmol), DIPEA (1.05 g, 8.1 mmol), and Pd
(dppf)Cl2.CH2Cl2 (44 mg, 54 µmol) in aqueous dioxane (30 mL dioxane, 5 mL
water) was heated at 80 °C under N2 atmosphere overnight. Water and EtOAc were
added. The organic phase was washed with 1M HCl and brine, dried over MgSO4,
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ﬁltered and concentrated. To the residue, 1 M NaOH (20 mL) was added. The
reaction was stirred at room temperature for 3 h. A spoonful of charcoal was added.
The mixture was stirred for 1 h and ﬁltered through a pad of celite. The mother
liquid was washed twice with CH2Cl2 and acidiﬁed with concentrated H3PO4.
EtOAc was added. The organic phase was washed with 1M HCl and brine, dried
over MgSO4, ﬁltered, and concentrated. The residue was recrystallized from water/
MeOH. The title compound was obtained as a white solid (0.77 g, 70% yield, 100%
purity). 1H NMR (600MHz, Methanol-d4): δ ppm 8.11 (t, J= 1.7 Hz, 1H),
7.78–7.82 (m, 2H), 7.70 (d, J= 8.5 Hz, 1H), 7.56 (t, J= 7.8 Hz, 1H), 6.92–6.99 (m,
2H), 6.86–6.90 (m, 1H), 6.72 (d, J= 1.8 Hz, 1H), 6.68 (dd, J= 8.8, 2.1 Hz, 1H). MS
(ESI+) m/z 404 [M+H]+.
Synthesis of 2-Hydroxyethyl-4-{[(5′-ﬂuoro-2′-hydroxybiphenyl-3-yl)sulfonyl]
amino}-2-hydroxybenzoate (KAN0438757): A mixture of 4-{[(5′-ﬂuoro-2′-
hydroxybiphenyl-3-yl)sulfonyl]amino}-2-hydroxybenzoic acid (0.020 g, 0.050
mmol), ethylene glycol (400 µL), and conc. H2SO4 was stirred at 80 °C for 1 day.
The reaction mixture was diluted with MeCN and puriﬁed by preparative HPLC
(Gilson HPLC system; ACE C8 (5 µm, 21 × 50 mm) column; 0.1%TFA in MilliQ
H2O/MeCN as mobile phase; fractions were collected based on the UV-signal). The
title compound was obtained in 100% yield (22 mg, 97% purity). 1H NMR (600
MHz, DMSO-d6): δ ppm 10.91 (s, 1H), 10.60 (s, 1H), 9.82 (s, 1H), 8.11 (t, J= 1.7
Hz, 1H), 7.83 (d, J= 7.6 Hz, 1H), 7.78 (d, J= 8.8 Hz, 1H), 7.71 (d, J= 8.5 Hz, 1H),
7.63 (t, J= 7.9 Hz, 1H), 7.12 (dd, J= 9.5, 3.1 Hz, 1H), 7.03–7.09 (m, 1H), 6.96 (dd,
J= 9.2, 4.9 Hz, 1H), 6.73 (dd, J= 8.7, 2.0 Hz, 1H), 6.70 (d, J= 2.1 Hz, 1H), 4.90 (t,
J= 5.6 Hz, 1H), 4.23–4.29 (m, 2H), 3.60–3.70 (m, 2H). 13C NMR (151 MHz,
DMSO-d6) δ ppm 168.5 (s), 161.2 (s), 155.7 (d, J= 234.9 Hz), 150.7 (d, J= 1.5 Hz),
144.4 (s), 139.0 (s), 138.4 (s), 133.7 (s), 131.6 (s), 129.4 (s), 127.2 (s), 126.4 (d, J=
7.5 Hz), 125.2 (s), 117.2 (d, J= 8.0 Hz), 116.1 (d, J= 23.3 Hz), 115.8 (d, J= 22.4
Hz), 109.5 (s), 108.0 (s), 105.3 (s), 66.7 (s), 58.9 (s). MS (ESI+) m/z 448 [M+H]+.
KAN0438757 was also prepared on a 6-g scale according to a similar protocol
with some minor changes, such as a lower temperature (50 °C for 1 week) and
extractive workup (EtOAc).
Isothermal titration calorimetry. ITC was performed for the titration of 200 μM
KAN0438241 into 20 μM PFKFB3 protein. Raw ITC data was recorded for 12 × 3
μl injections (preceded by 0.4 μl injection). Data was collected with PEAQ-ITC
system (MicroCal™, Malvern Instruments) at 25 °C, 10 μcal/s Reference Power,
High Feedback, and 750 rpm stirring rate. A constant value of the heat of dilution
was ﬁtted along with the binding parameters. Data analysis performed with
dedicated PEAQ-ITC analysis software (MicroCal, Malvern Instruments).
Methods for measurement of enzymatic activity. The kinase activity of the bi-
functional enzyme was quantiﬁed based on the production of ADP and F-2,6-P2
from ATP by ADP-GloTM Kinase Assay (Promega). The assay was performed in
two steps; ﬁrst, after the kinase reaction, an equal volume of ADP-GloTM Reagent
was added to terminate the kinase reaction and deplete the remaining ATP. Sec-
ond, the Kinase Detection Reagent was added to simultaneously convert ADP to
ATP and allow the newly synthesized ATP to be measured using a luciferase/
luciferin reaction. The light generated was measured using a luminescence counter
(1450 MicroBeta TriLux). The assay was performed in white 384-well plates
(OptiPlate, 6007299, PerkinElmer) by consecutive additions of a test compound
solution (0.1 µL, serial diluted in DMSO from compound DMSO stock solution
and dispensed by acoustic dispensing from UV-star 384-well plate 7360153, VWR),
enzyme solution (5 µL) and substrate (fructose-6-phosphate (F6P) and adenosine-
5′-triphosphate (ATP)) containing solution (5 µL). Controls in the absence of
inhibitor (uninhibited activity, only DMSO), 100 nM of an in-house inhibitor (QC,
50% inhibited kinase activity), and 49.5 µM of an in-house inhibitor (completely
inhibited kinase activity) were included in the plate. Four reference dose–response
curves, one of them being the QC compound, were included and serial diluted as
the test compounds. The ﬁnal concentrations of all reagents per well were 50 mM
Tris–HCl at pH 8.0, 10 mM MgCl2, 5 mM NaPi at pH 8.0, 81.48 nM PFKFB3 or
145 nM PFKFB4, 8 µM ATP, 100 µM F6P (acid treated and then neutralized to
remove any contaminating F-2,6-P234), 0.005% Tween-20 and 1 mM dithiothreitol.
Enzyme, compounds, and controls were pre-incubated at room temperature for 15
min before the addition of substrate solution. The enzymatic reaction was allowed
to proceed for 20 min and the reaction was terminated by the addition of ADP-
GloTM Reagent (10 µL) to all wells followed by 40 min incubation at room tem-
perature. After addition of Kinase Detection Reagent (20 µL) to all wells, the plate
was incubated for 30 min at room temperature, followed by measurement in 1450
MicroBeta TriLux. All plates were centrifuged after each addition. As described
above, controls were included on each plate to deﬁne the values for uninhibited and
fully inhibited reactions and these values were used to calculate the % inhibition of
the enzymatic reaction at any given compound concentration. The inhibitory
potency or IC50 values of test compounds on the kinase activity of the enzymes
were calculated using a four-parameter model (model 205) in XLﬁt (IDBS Acti-
vityBase XE Runner).
Method for quantiﬁcation intracellular F-2,6-P2. Quantiﬁcation of F-2,6-P2 was
performed as described by Van Schaftingen et al.34. The assay is based on the
potent activation of pyrophosphate-dependent phosphofructokinase-1 (PPi-PFK)
from potato tubers by F-2,6-P2. The use of a series of coupled enzymes leads to a
consumption of nicotinamide adenine dinucleotide (NADH) that can be followed
spectrophotometrically. PANC-1, NUGC-3, SW620, or MIA PaCa-2 cells were
seeded at a density of 2.5 × 104–3.5 × 104 cells per well (96-well, CLS3595, Sigma-
Aldrich) and incubated overnight at 37 °C and 5% CO2. Following day growth
medium was replaced with starvation medium, DMEM/F12 without phenol red
and glucose-free (SVA) supplemented with 0.25% FBS (Invitrogen). The plates
were incubated for 18 h at 37 °C and 5% CO2. After 18 h of starvation, the cells
were induced with compound or control solutions (100 µL). Compounds were
either tested in two concentrations (50 and 10 µM) or in dose–response curves
(starting from 50 µM), a dose–response curve of a reference inhibitor was included
and all compounds were tested on duplicate plates. Compounds (in 96-well plates
CLS 3365, Sigma-Aldrich) were serial diluted in DMSO with Janus automated
liquid handling workstation (PerkinElmer). Compounds were transferred to a
Greiner deep well plate (736-0155, VWR) with starvation medium. The start
concentration of compounds in the dilution plate was 100 µM, 1% DMSO. For
compounds tested as single points, 10 mM compound solutions were diluted 5-fold
in DMSO to 2 mM, followed by the transfer to separate dilution plates with star-
vation medium. The ﬁnal concentrations of compounds in these dilution plates
were 100 or 20 µM, respectively, and ﬁnal concentration of DMSO was 1%. The
plates were incubated at 37 °C and 5% CO2 for 1 h, followed by the addition of 20
mM D-glucose (10 µL) in starvation medium. Controls, with and without glucose
(1 mM), were included. After 2 h of incubation, the supernatants were discarded
and the cells lysed by the addition of 250 mM NaOH (25 µL). The plates were
incubated at 37 °C and 5% CO2 for 5 min followed by an addition of MilliQ dH2O
(75 µL). The supernatants were further diluted with 210 µL MilliQ dH2O to a ﬁnal
concentration of 20 mM NaOH. 200 µL were transferred to NUNC 96-well plates
(VWR) and the plates were sealed and stored at −20 °C until analysis. Plates stored
at −20 °C were thawed and the F-2,6-P2 quantiﬁcation was initiated by transferring
40 µL from each well of the NUNC plate to the corresponding position in a
transparent 96-well SpectraPlate-MB (PerkinElmer). In order to ensure that all F-
2,6-P2 measured values were within the linear range of response (between 0 and 1
nM ﬁnal concentration of F-2,6-P2
34), the same sample volume of an in-house
produced F-2,6-P2 standard was included on each plate. The following reagents
were added per well: 50 mM Tris–acetate pH 8.0, 0.15 mM NADH, 2 mM Mg
(OAc)2, 1 mM F6P (acid treated and then neutralized to remove any contaminating
F-2,6-P34), 0.5 mM pyrophosphate, 0.45 U/mL aldolase, 5 U/mL triose phosphate
isomerase, 1.7 U/mL glycerol-3-phosphate dehydrogenase, 0.01 U/mL
pyrophosphate-dependent phosphofructokinase from potato tubers and 0.2 mg/mL
bovine serum albumin. The coupled enzymatic reaction was allowed to proceed for
45 min at room temperature and the absorbance at 340 nm was continuously
measured every 30 s (SpectraMax plate reader, Molecular Devices). The measured
absorbance was proportional to the concentration of NADH, which in turn was
proportional to the levels of F-2,6-P2 within the linear range. This was deﬁned by
the F-2,6-P2 controls. The IC50 values for test compounds were calculated using a
four-parameter model (model 205) in XLﬁt (Excel) and in XLﬁt (IDBS
ActivityBase).
Measurement of inhibition of cell proliferation. Cell proliferation was assayed by
quantifying total cellular protein levels after indicated treatments and incubation
times using the Sulphorhodamine B kit, TOX6 (Sigma-Aldrich). MIA PaCa-2,
PANC1, SW620, and SW480 cells were plated at a density of 6 × 103 cells/well in
96-well plates (CLS3596, Sigma-Aldrich) and allowed to attach overnight. The
following day, compounds were diluted in dose–response curve mode, required
volume was transferred to assay medium to a maximal DMSO concentration of
0.1%. The diluted compounds were added to the cells with a starting dose–response
concentration of 100 µM, all compounds were tested in duplicate plates. After 72 h
of incubation with compounds, total protein per well was precipitated using TCA
according to the manufacturer's instructions; the sulphorhodamine dye was added
to the air-dried wells. After 20 min incubation at room temperature, the dye was
discarded and the samples were gently rinsed with 1% HOAc until clear. After air
drying, bound dye was solubilized in 10 mM Tris base, and the absorbance of dye
was measured at 565 nm. To quantify growth, samples were collected also at t= 0
h, and the resulting absorbance was set to 100%. The measured effect on cancer cell
proliferation was quantiﬁed as the ratio between 72 h value and the 0 h value in
percent, and this value was subsequently divided with the 72 h 0.1% DMSO control
sample in percent demonstrating the growth-inhibitory effect.
Crystallization. Diffraction data have been collected on BL14.1 operated by the
Helmholtz-Zentrum Berlin (HZB) at the BESSY II electron storage ring (Berlin-
Adlershof, Germany)57. Indexing, reduction, and scaling of diffraction data were
performed using XDS58. Crystallographic reﬁnement and model building was
performed using Refmac5 and Coot59–61. Structure quality was assessed using
MolProbity62. We refer to Supplementary Table 1 for crystallographic data col-
lection and reﬁnement statistics.
Data availability
All of the structural data from this study have been submitted to the pdb database (PDB
ID 6ETJ). All other supporting data from this study are available from the article and
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